

<p style="text-align: center;">Boaz Hirshberg, MD SVP, Clinical Development Unit Head, Internal Medicine at Regeneron</p>
--

Boaz Hirshberg, MD, joined Regeneron in 2021 and serves as Senior Vice President, Clinical Development Unit Head for Internal Medicine. In his role he spearheads strategic program direction and oversees both early and late-stage clinical development across diverse therapeutic areas including ophthalmology, immunology, inflammation, infectious diseases, cardiovascular health, obesity and metabolism, and several rare diseases. Under his leadership, numerous programs have advanced into clinic trials, with several reaching later stages of development and contributing to multiple global filings supporting Biologics License Applications (BLAs) and supplemental BLAs.

Before joining Regeneron, Dr. Hirshberg served as Executive Vice President and Chief Medical Officer at BOL Pharma. He also co-founded and served as CEO and CMO of Regio Biosciences, a biotech company focused on developing novel therapies to reduce plaque in peripheral arteries and the heart, targeting atherosclerosis.

Dr. Hirshberg spent twelve years at AstraZeneca/MedImmune culminating in his role as Vice President, Clinical Therapeutic Area Head for Cardiovascular, Renal and Metabolism (CVRM) at MedImmune. He established a robust CVRM clinical team, comprising more than fifty research physicians, clinical scientists, and operations team members, managing a pipeline that spanned cardiovascular, diabetes, obesity, non-alcoholic steatohepatitis (MASH), and renal diseases. He led multiple international programs, advancing eight into clinical trials, with several progressing to Phase 2. As a global clinical lead for the Onglyza® franchise, Dr. Hirshberg was instrumental in delivering the SAVOR outcomes study and multiple global submissions, including the New Drug Applications (NDAs) for Kombiglyze®XR and Qtern®.

Earlier in his career, Dr. Hirshberg served as Early Clinical Lead for diabetes at Pfizer for three years. He earned his undergraduate and medical degrees from the Hebrew University and is board-certified in Internal Medicine, having completed his residency at the Hadassah Medical Center in Jerusalem. He furthered his expertise with an endocrine fellowship at the National Institute of Diabetes and Digestive and Kidney Diseases and obtained an MBA in Health Care Administration from Wilmington University. Dr. Hirshberg has co-authored over 130 papers and chapters, contributing significantly to medical literature.